Sanofi's Praluent Closes Gap On Amgen's Repatha In Europe
This article was originally published in Scrip
With its formal EU approval now announced, Sanofi SA and Regeneron Pharmaceuticals Inc.'s powerful cholesterol-lowering drug Praluent (alirocumab) will now catch up with its key competitor there, Amgen's Repatha (evolocumab), but their high price tags will probably mean a slow up-take for both therapies in the region.
You may also be interested in...
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.